Sectoral Asset Management Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Sectoral Asset Management Inc

$203 Million
Q1 2024

A detailed history of Sectoral Asset Management Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Sectoral Asset Management Inc holds 7,682 shares of ARWR stock, worth $199,655. This represents 0.11% of its overall portfolio holdings.

Number of Shares

7,682

Previous 8,182 6.11%

Holding current value

$199,655

Previous $250,000 12.4%

% of portfolio

0.11%

Previous 0.11%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$27.21 - $39.48 $13,605 - $19,740	-500 Reduced 6.11%	7,682 $219,000
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $3.17 Million - $4.63 Million	-149,370 Reduced 94.81%	8,182 $250,000
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $357,106 - $491,770	13,630 Added 9.47%	157,552 $4.23 Million
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $3.62 Million - $5.96 Million	143,922 New	143,922 $5.13 Million
Q4 2022 Feb 10, 2023	SELL	$28.0 - $40.56 $95,200 - $137,904	-3,400 Reduced 3.44%	95,400 $3.87 Million

Q3 2022 Nov 10, 2022	SELL	$29.63 - $48.31 $533,340 - $869,580	-18,000 Reduced 15.41%	98,800 $3.27 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $80,591 - $146,769	-2,900 Reduced 2.42%	116,800 $4.11 Million
Q1 2022 May 10, 2022	BUY	$39.62 - $69.97 $590,338 - $1.04 Million	14,900 Added 14.22%	119,700 $5.51 Million
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $6.09 Million - $8.65 Million	104,800 New	104,800 $6.95 Million
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $508,113 - $784,431	-15,300 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $399,636 - $662,031	15,300 New	15,300 $661,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.75B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sectoral Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sectoral Asset Management Inc with notifications on news.

Account

Sectoral Asset Management Inc Arrowhead Pharmaceuticals, Inc. Transaction History